^
Association details:
| Biomarker: | LDH elevation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Libtayo (cemiplimab-rwlc) (PD1 inhibitor) + fianlimab (REGN3767) (LAG-3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
150P - Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel): subgroup analysis
Published date:
12/01/2022
Excerpt:
In pts with LDH>ULN at BL, the ORR for EC6+15 was 57.1%, the DCR was 71.4, and the mDOR was NR (95% CI, 7.3–NE). In pts with LDH>ULN at BL and any M1c, the ORR for EC6+15 was 53.8%, the DCR was 69.2%, and the mDOR was NR (95% CI, 5.7–NE)….Despite small numbers in subgroups, the efficacy analysis from EC6 and EC15 combined demonstrates high activity of fianlimab in combination with cemiplimab in pts with advanced mel and poor prognosis features at BL.
Trial ID:
